Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas
- 28 February 2024
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 37 (5) , 100463
Abstract
No abstract availableKeywords
Funding Information
- Roche
- AstraZeneca
This publication has 68 references indexed in Scilit:
- HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional seriesBreast Cancer Research and Treatment, 2023
- Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer DatabaseJAMA Oncology, 2023
- Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancerThe Breast, 2022
- Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancerBreast Cancer, 2022
- Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en FranceAnnales de Pathologie, 2021
- Prognostic impact of HER2-low expression in hormone receptor positive early breast cancerThe Breast, 2021
- HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancerBreast Cancer Research and Treatment, 2021
- 22P HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysisAnnals of Oncology, 2021
- Comprehensive Molecular Portraits of Invasive Lobular Breast CancerCell, 2015
- Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patternsCancer, 1996